A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

This study is for people in the UK who have been diagnosed with a type of lung cancer called non-small cell lung cancer. This cancer is considered 'advanced' if it has spread beyond the original site, meaning it might be in other parts of the body (metastatic), or if it's grown too much to be removed by surgery (locally advanced, unresectable). For this study, doctors have also found a specific marker called 'PD-L1' on the cancer cells, which helps them decide if this type of treatment is suitable.

The trial is a 'Phase 3' study, which is the final stage of testing a new treatment before it can be approved for wider use. It's designed to be a very fair comparison: some people will receive a new combination of medications (ociperlimab and tislelizumab), while others will receive a treatment that's currently used (pembrolizumab, also known as KEYTRUDA). To make sure the results are unbiased, neither you nor your doctors will know which treatment you are getting – this is called a 'double-blind' study. Everyone will also receive a saline solution, which is just sterile salt water, as part of their treatment administration.

The main thing the researchers want to find out is whether the new combination helps people live longer than those on the standard treatment. They will also be looking closely at how long it takes for the cancer to grow or spread, if the tumours shrink, and for how long. Another important aspect is how the treatments affect your daily life and well-being, often called 'quality of life'. They will also carefully record any side effects you experience to fully understand the safety of these treatments.